DUBLIN, October 3, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Prenatal & Maternal Diagnostic Market Analysis to 2021" report to their offering.

The global prenatal, maternal and newborn screening diagnostic test market will be worth over $10.5 billion, up from $8 billion today

This market is subdivided into ultrasound, fetal MRI, maternal serum and noninvasive prenatal screening technologies and will see a five year compound annual growth rate of 4.1%. The new report, entitled GLOBAL PRENATAL AND MATERNAL DIAGNOSTIC MARKET ANALYSIS to 2021 indicates that the launch of noninvasive prenatal screening tests (NIPTs) in 2011 dramatically altered the market dynamic, and this sub-section of the market will see an 18% CAGR to 2021.  This is at the expense of more invasive techniques as chorionic villus sampling (CVS) or amniocentesis.

Prenatal tests (fetus, embryos and newborns) currently on the market analyze chromosomes, DNA, RNA, genes, and/or gene products to determine whether an abnormality is present that is causative of a specific disease. Since 2011, the launch of noninvasive prenatal tests (NIPTs) is revolutionizing the prenatal screening industry providing detection rates of >99% and false positive rates of <0.1%. These screening results are only indicative of the risk and not confirmative. To confirm positive results of NIPT screening tests, prenatal diagnostic tests such as amniocentesis and chorionic villus sampling (CVS) are performed. Prior to NIPTs, ultrasound and maternal serum tests were routinely used to screen fetusus for genetic abnormalities.

Globally, 50 countries have effective newborn genetic test programs, the implementation of which is in various stages. In the U.S., four million newborns are tested annually, with 3,000 found to have metabolic and genetic diseases. The purpose of newborn screening is to identify affected newborns quickly and provide them with treatment to prevent mental retardation, prolonged illness and death. The newborn genetic screening market is crowded with different technologies, the common being tandem mass spectrometry, pulse oximetry, enzyme-based assays, DNA assays and electrophoresis.

The global prenatal and maternal diagnostic test market is assessed with respect to:

• Fetal Ultrasound
• Prenatal MRI Screening
• Maternal Serum Screening Tests
• Noninvasive Prenatal Tests (NIPTs) using cffDNA
• NIPTs by Product
• Prenatal Diagnostic Invasive Tests
• Newborn Screening for Genetic Diseases
• Newborn Screening Market by Technology
• Preimplantation Screening/Diagnosis (PGS/PGD) and carrier screening tests

Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries:

• Molecular Diagnostics Market
• Liquid Biopsy Market
• Personalized Medicine Diagnostics Market
• In vitro Diagnostics (IVD) Market

Key Topics Covered:

1.0 Introduction

2.0 Prenatal Pregnancy Complications: An Overview

3.0 Types of Genetic Diseases in Fetuses: An Overview

4.0 Genetic Counseling: An Overview

5.0 Prenatal Screening for Genetic Diseases: An Overview

6.0 Newborn Screening

7.0 Preconception/Carrier Screening

8.0 Pregnancy, Prenatal, Newborn and PGD-Related Technologies: An Overview

9.0 Market Analysis

10.0 Other Genetic Testing-Related Markets

11.0 Market SWOT and Strategy Analysis

12.0 Company Profiles    

- 23andMe Inc.

- Abbott Laboratories

- Abbott Molecular Inc.

- Abcam plc

- AB Sciex LLC

- Adaltis S.r.l

- Adaptive Biotechnologies Corp.

- Affymetrix Inc.

- Agena Biosciences Inc.

- Agilent Technologies Inc.

- Ambry Genetics Corp.

- Analogic Corp.

- Ariosa Diagnostics Inc.

- Ansh Labs

- Appistry Inc.

- ARUP Laboratories

- AssureRx Health Inc.

- Asuragen Inc.

- Athena Diagnostics Inc.

- AutoGenomics Inc.

- Base4 Innovation Ltd.

- Beckman Coulter Inc.

- Berry Genomics Co., Ltd.

- Bina Technologies Inc.

- Bio-Rad (Israel) Laboratories Inc.

- BGI

- Blueprint Genetics Oy

- Boreal Genomics Inc.

- Cambridge Epigenetix Ltd.

- Claris Lifesciences

- CeGaT GmbH

- Centogene AG

- Chromosystems Instruments & Chemicals GmbH

- Chronix Biomedical Inc.

- Claritas Genomics Inc.

- CLC bio A/S

- Combimatrix Corp.

- Contec Medical Systems Co., Ltd.

- Coriell Life Sciences Inc.

- Correlagen Diagnostics Inc.

- Counsyl Inc.

- Courtagen Life Sciences Inc.

- Creative Diagnostics

- Cynvenio Biosystems Inc.

- Diagnostic Automation/Cortex Diagnostics Inc.

- Demeditec Diagnostics GmbH

- DRG International Inc.

- DNA Electronics Ltd.

- DNA Link Inc.

- DNAnexus Inc.

- Eagle Biosciences Inc.

- Eagle Genomics Ltd.

- Enzymatics Inc.

- Esoate SpA

- Eurofins MWG Operon Inc.

- Exiqon A/S

- Fakuda Denshi Co, Ltd.

- GATC Biotech AG

- GE Healthcare Ltd.

- GenapSys Inc.

- Gene by Gene Ltd.

- Genection Inc.

- GeneDx Inc.

- GenePeeks Inc.

- Genesis Genetics

- Genetadi Biotech S.L.

- Genoma Group Srl

- Genomed AG

- GenPath Diagnostics

- Genway Biotech Inc.

- Good Start Genetics Inc.

- Hitachi Medical Systems America Inc.

- Hologic Inc.

- Illumina Inc.

- INEX Innovations Exchange Pte., Ltd.

- Invitae Corp.

- Laboratory Corporation of America Inc.

- LifeCodexx AG

- Monobind Inc.

- Multiplicom NV

- Myriad Genetics

- Natera Inc.

- Natus Medical Inc.

- NewGene Ltd.

- NIPD Genetics Ltd.

- Oxford Gene Technology

- Parabase Genomics Inc.

- Pathway Genomics Corp.

- PerkinElmer Life and Analytical Sciences Inc.

- Premaitha Health PLC

- Progenity Inc.

- Qiagen N.V.

- Quest Diagnostics Inc.

- Ravgen Inc.

- Recombine Inc.

- Reproductive Genetics Institute Inc.

- Reprogenetics Laboratories

- Sebia Inc.

- Sequenom Inc.

- SeraCare Life Sciences Inc.

- Siemens Healthcare

- Sophia Genetics SA

- SpOtOn Clinical Diagnostics Ltd.

- Stra Biotech GmbH

- Sygnis AG

- SynapDx Corp.

- Thermo Fisher Scientific Inc.

- Transgenomic Inc.

- Trivitron Healthcare Private Ltd.

- Trovagene Inc.

- Tute Genomics Inc.

- Warp Drive Bio LLC

- ZS Genetics Inc.

- Zymo Research Corporation

For more information about this report visit http://www.researchandmarkets.com/research/lznvhg/global_prenatal

Related Topics: Diagnostics, Women's Health

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets